Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab +/- Tremelimumab or Danvatirsen in R/R DLBCL
NCT02549651Phase 1Completed
- Sponsor
- MedImmune
- Start
- Jul 2016
- Primary completion
- Feb 2019
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 4
01
Overview
Phase 1, open-label trial of durvalumab in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by MedImmune. Primary endpoints: Number of subjects reporting adverse events and serious adverse events and Number of subjects experiencing dose-limiting toxicities. Started Jul 2016; status: completed.
02
Drugs
durvalumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02549651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02549651.